Published in Drug Metab Dispos on April 01, 2010
Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev (2010) 1.36
EET signaling in cancer. Cancer Metastasis Rev (2011) 1.18
A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomics. Top Curr Chem (2013) 1.07
Dietary Glucosinolates Sulforaphane, Phenethyl Isothiocyanate, Indole-3-Carbinol/3,3'-Diindolylmethane: Anti-Oxidative Stress/Inflammation, Nrf2, Epigenetics/Epigenomics and In Vivo Cancer Chemopreventive Efficacy. Curr Pharmacol Rep (2015) 0.83
Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions. Chem Res Toxicol (2016) 0.78
Cytotoxic and potent CYP1 inhibitors from the marine algae Cymopolia barbata. Org Med Chem Lett (2012) 0.78
Effects of aqueous cinnamon extract on chemically-induced carcinoma of hamster cheek pouch mucosa. Biochem Biophys Rep (2017) 0.75
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer (2006) 3.52
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc (1976) 3.19
Chemoprevention of cancer. Cancer Res (1985) 2.78
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res (2009) 2.62
Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res (2006) 2.49
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids (2006) 1.89
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol (1997) 1.63
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol (2007) 1.53
In utero exposure of mice to dibenzo[a,l]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor. Cancer Res (2006) 1.24
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther (2008) 1.19
Overview of mechanisms of cancer chemopreventive agents. Mutat Res (2005) 1.17
Indole-3-carbinol in the maternal diet provides chemoprotection for the fetus against transplacental carcinogenesis by the polycyclic aromatic hydrocarbon dibenzo[a,l]pyrene. Carcinogenesis (2006) 1.07
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
Fetal mouse Cyp1b1 and transplacental carcinogenesis from maternal exposure to dibenzo(a,l)pyrene. Cancer Prev Res (Phila) (2008) 1.05
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther (2008) 0.99
Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model. Cancer Gene Ther (2007) 0.95
Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling. Chem Biol Interact (2008) 0.94
Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum Gene Ther (2008) 0.87
CYP17 inhibitors for prostate cancer treatment--an update. Curr Med Chem (2008) 0.85
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Ther (2008) 0.82
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
The DNA sequence of the human X chromosome. Nature (2005) 6.97
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46
Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest (2007) 4.86
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 4.34
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem (2004) 4.10
Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell (2006) 4.03
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res (2007) 3.84
Detection of large numbers of novel sequences in the metatranscriptomes of complex marine microbial communities. PLoS One (2008) 3.83
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77
Genome characteristics of facultatively symbiotic Frankia sp. strains reflect host range and host plant biogeography. Genome Res (2006) 3.53
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell (2005) 3.52
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res (2007) 3.43
PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2006) 3.29
Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem (2002) 3.24
Preceramic adoption of peanut, squash, and cotton in northern Peru. Science (2007) 3.23
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09
Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol (2013) 3.07
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87
Nonlinear cancer response at ultralow dose: a 40800-animal ED(001) tumor and biomarker study. Chem Res Toxicol (2009) 2.80
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology (2003) 2.70
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology (2012) 2.62
Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab (2008) 2.57
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56
Dielectrophoretic Separation of Cancer Cells from Blood. IEEE Trans Ind Appl (1997) 2.45
Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science (2003) 2.41
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology (2004) 2.40
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol (2011) 2.37
Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 2.35
The draft genome of watermelon (Citrullus lanatus) and resequencing of 20 diverse accessions. Nat Genet (2012) 2.33
Point of care diagnostics: status and future. Anal Chem (2011) 2.31
Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab (2010) 2.30
Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther (2005) 2.30
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev (2004) 2.30
Protein intake and incident frailty in the Women's Health Initiative observational study. J Am Geriatr Soc (2010) 2.28
Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res (2008) 2.27
Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev (2006) 2.23
Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci (2003) 2.20
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis (2006) 2.18
Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol (2006) 2.17
C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem (2002) 2.16
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A (2011) 2.14
sSgo1, a major splice variant of Sgo1, functions in centriole cohesion where it is regulated by Plk1. Dev Cell (2008) 2.12
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab (2009) 2.09
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol (2008) 2.04
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem (2003) 2.04
Evaluation and comparison of food records, recalls, and frequencies for energy and protein assessment by using recovery biomarkers. Am J Epidemiol (2011) 2.04
A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 1.99
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem (2002) 1.97
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92
Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens (2011) 1.91
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90
Why stainless steel corrodes. Nature (2002) 1.90
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys (2003) 1.88
MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets. Genome Biol (2012) 1.88
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 1.85
Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest (2007) 1.85
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun (2013) 1.84
Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene (2008) 1.82
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
LC-MS-based metabolomics in drug metabolism. Drug Metab Rev (2007) 1.79
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol (2011) 1.76
Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol Cell Biol (2003) 1.75
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab (2005) 1.72
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med (Berl) (2005) 1.71
Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol (2005) 1.71
Haploinsufficiency of SGO1 results in deregulated centrosome dynamics, enhanced chromosomal instability and colon tumorigenesis. Cell Cycle (2012) 1.71
Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest (2010) 1.70
Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma (2011) 1.70
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab (2010) 1.69
Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol (2008) 1.69
Enhanced recovery after surgery programs versus traditional care for colorectal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum (2013) 1.69
Biases introduced by choosing controls to match risk factors of cases in biomarker research. Clin Chem (2012) 1.69
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature (2012) 1.68